Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: ATAI Life Sciences (ATAI), AstraZeneca (AZN)

Tipranks - Tipranks - Thu Jan 22, 11:44AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ATAI Life Sciences (ATAI – Research Report), AstraZeneca (AZN – Research Report) and Zentalis Pharmaceuticals (ZNTL – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

ATAI Life Sciences (ATAI)

H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on ATAI Life Sciences today and set a price target of $15.00. The company’s shares closed last Wednesday at $3.83.

According to TipRanks.com, Trucchio is a 5-star analyst with an average return of 32.0% and a 53.4% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Arrowhead Pharmaceuticals, and Alto Neuroscience, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ATAI Life Sciences with a $13.25 average price target, representing a 243.3% upside. In a report released yesterday, Guggenheim also initiated coverage with a Buy rating on the stock with a $11.00 price target.

See the top stocks recommended by analysts >>

AstraZeneca (AZN)

Morgan Stanley analyst Sarita Kapila maintained a Buy rating on AstraZeneca today and set a price target of $104.00. The company’s shares closed last Wednesday at $89.60.

Kapila has an average return of 3.0% when recommending AstraZeneca. ;'>

According to TipRanks.com, Kapila is ranked #9785 out of 12040 analysts.

AstraZeneca has an analyst consensus of Strong Buy, with a price target consensus of $103.00.

Zentalis Pharmaceuticals (ZNTL)

H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on Zentalis Pharmaceuticals today and set a price target of $10.00. The company’s shares closed last Wednesday at $2.85, close to its 52-week low of $1.61.

According to TipRanks.com, Maldonado is a 5-star analyst with an average return of 26.2% and a 56.5% success rate. Maldonado covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Monopar Therapeutics Inc, and NovaBridge Biosciences. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zentalis Pharmaceuticals with a $6.60 average price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).